Chemical formula: C₂₂H₁₉ClO₃ Molecular mass: 366.837 g/mol PubChem compound: 74989
Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III).
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| P01AX06 | Atovaquone | P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01A Agents against amoebiasis and other protozoal diseases → P01AX Other agents against amoebiasis and other protozoal diseases |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| MEPRON Oral suspension | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| WELLVONE Oral suspension | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Atovaquone is an active ingredient of these brands:
Austria (AT)
Finland (FI)
Ireland (IE)
Israel (IL)
Lithuania (LT)
Malta (MT)
New Zealand (NZ)
Nigeria (NG)
Singapore (SG)
South Africa (ZA)United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
